Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.

Cancer immunology, immunotherapy : CII - 1 Jun 2015

Prasmickaite Lina, Berge Gisle, Bettum Ingrid J, Aamdal Steinar, Hansson Johan, Bastholt Lars, Øijordsbakken Miriam, Boye Kjetil, Mælandsmo Gunhild M

Abstract excerpt

Malignant melanoma is highly aggressive cancer with poor prognosis and few therapeutic options. Interferon alpha (IFN-α) has been tested as adjuvant immunotherapy in high-risk melanoma patients in a number of studies, but its beneficial role is controversial. Although IFN-α treatment can prolong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Osteopontin

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Randomized Controlled Trials as Topic

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25832001
DOI: 10.1007/s00262-015-1686-4
PMCID: PMC11029450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25832001-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.PMID 25832001Read ↗

Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.Semantic proximity Read ↗

SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.Semantic proximity Read ↗

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.Semantic proximity Read ↗

Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4.Semantic proximity Read ↗

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Semantic proximity Read ↗

Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.Semantic proximity Read ↗

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.Semantic proximity Read ↗

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.Semantic proximity Read ↗

Influence of genetic variants in type I interferon genes on melanoma survival and therapy.Semantic proximity Read ↗

Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis.Semantic proximity Read ↗

Role of osteopontin in tumour progressionSemantic proximity Read ↗

Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.